About Tubulin polyglutamylase complex subunit 2
Tubulin polyglutamylase complex subunit 2 (TPGS2) is a protein
from Homo sapiens identified by UniProt accession
Q68CL5, 300 residues long.
MolForge cross-references it against 0 known binders and
80 disease associations.
Target properties
| Protein name | Tubulin polyglutamylase complex subunit 2 |
|---|
| UniProt accession | Q68CL5 |
|---|
| Gene | TPGS2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 300 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (80)
Diseases linked to this target (Open Targets).
- reaction time measurement · score 0.17
- hypertrophic cardiomyopathy · score 0.16
- electrocardiography · score 0.15
- genetic disorder · score 0.15
- waist-hip ratio · score 0.12
- risk-taking behaviour · score 0.11
- smoking status measurement · score 0.11
- attention deficit hyperactivity disorder · score 0.10
- antisocial behaviour measurement · score 0.10
- substance abuse · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q68CL5-F1 | alphafold | PREDICTED | 73.25 | — |
Amino-acid sequence (300 residues)
MEEEASSPGL GCSKPHLEKL TLGITRILES SPGVTEVTII EKPPAERHMI SSWEQKNNCV MPEDVKNFYL MTNGFHMTWS VKLDEHIIPL GSMAINSISK LTQLTQSSMY SLPNAPTLAD LEDDTHEASD DQPEKPHFDS RSVIFELDSC NGSGKVCLVY KSGKPALAED TEIWFLDRAL YWHFLTDTFT AYYRLLITHL GLPQWQYAFT SYGISPQAKQ WFSMYKPITY NTNLLTEETD SFVNKLDPSK VFKSKNKIVI PKKKGPVQPA GGQKGPSGPS GPSTSSTSKS SSGSGNPTRK
Explore Tubulin polyglutamylase complex subunit 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets